Palovarotene

Drug Profile

Palovarotene

Alternative Names: Clm-001; R-667; RG-667; RO-3300074

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Roche
  • Developer Clementia Pharmaceuticals; Roche
  • Class Benzoic acids; Naphthalenes; Pyrazoles; Small molecules
  • Mechanism of Action Retinoic acid receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibrodysplasia ossificans progressiva
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fibrodysplasia ossificans progressiva
  • Discontinued Emphysema

Most Recent Events

  • 28 Mar 2017 Updated interim adverse events and efficacy data from a phase II open label extension study in Fibrodysplasia ossificans progressiva released by Clementia Pharmaceuticals
  • 14 Nov 2016 Clementia Pharmaceuticals suspends enrolment in a phase II trial for Fibrodysplasia ossificans progressiva in USA (NCT02521792)
  • 01 Nov 2016 Clementia Pharmaceuticals initiates an extension phase II trial for Fibrodysplasia ossificans progressiva (In adolescents, In adults, In children) in France (PO) (NCT02979769)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top